The Center for American Principles submitted a letter to the Senate Committee on Health, Education, Labor & Pensions (HELP) ahead of its June 17 business meeting, urging lawmakers to preserve strong and predictable patent rights for biopharmaceutical innovation.
In the letter, CAP argues that patent policy is a critical driver of medical innovation, helping ensure that high-risk research, complex therapies, and breakthrough treatments receive the investment necessary to reach patients. CAP notes that drug development often takes a decade or more, costs billions of dollars, and carries a high risk of failure, making reliable intellectual property protections essential to attracting private-sector investment.
The letter further explains that pharmaceutical innovation is cumulative, with researchers continuing to develop new formulations, delivery systems, manufacturing methods, and therapeutic applications long after a medicine’s initial approval. Protecting these advances encourages continued investment and helps deliver meaningful benefits to patients.
CAP also highlights the important role of generic competition, noting that generic and biosimilar medicines account for the vast majority of prescriptions filled in the United States while emphasizing that strong patent protections and affordable access have long coexisted within the U.S. healthcare system. The letter concludes that policymakers should carefully distinguish between genuinely abusive conduct and the ordinary operation of patent law in a technologically complex field, warning that weakening valid patent protections could reduce investment in the next generation of treatments and cures.